Filing Flows › Comparisons › TOVX vs BIOA
Theriva Biologics vs BioAge Labs: TOVX and BIOA compared
Theriva Biologics is the larger company: $300K of revenue in its latest quarter (Q1 2026) against $298K for BioAge Labs (Q3 2026).
Where the money goes: TOVX and BIOA
Theriva Biologics (TOVX) · Q1 2026
Theriva Biologics, Q1 2026: revenue $300K, operating margin -709.0%, net loss $2.0M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
BioAge Labs (BIOA) · Q3 2026
BioAge Labs, Q3 2026: revenue $298K (-86% year over year), net loss $33.5M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
| Theriva Biologics (TOVX) | BioAge Labs (BIOA) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q3 2026 |
| Revenue | $300K | $298K |
| Revenue growth, Y/Y | — | -86% |
| Operating margin | -709.0% | n/m |
| Net earnings | −$2.0M | −$33.5M |
| Net margin | -681.3% | — |
| Operating cash flow | −$2.5M | −$31.0M |
Questions
Which is bigger, Theriva Biologics or BioAge Labs?
Theriva Biologics is the larger company: $300K of revenue in its latest quarter (Q1 2026) against $298K for BioAge Labs (Q3 2026).
More: Theriva Biologics earnings · how Theriva Biologics makes money · BioAge Labs earnings · how BioAge Labs makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 5, 2026; 10-Q filed Nov 5, 2026). Fiscal quarters can end on different dates. Not investment advice.